

21^{ème} Édition

Journées de la Société Française de Myologie

20 - 22 Novembre 2024 | Polydome Clermont-Ferrand



Liste des Posters

#	NOM	PRÉNOM	TITRE DE L'ABSTRACT
1	BOURGUIBA VILLENEUVE	Aly	GDF5 therapeutic potential on neuromuscular junction defects
2	CARLIER	Andréa	Pan-therapy, CRISPR/Cas13-mediated, for centronuclear myopathies by targeting DYNAMIN 2
3	CIUMAS	Mariana	Administration continue et à cycle fixe de l'efgartigimod intraveineux pour la myasthénie généralisée : l'étude d'ADAPT NXT
4	FAIL	Aurélié	hGDF5-P: An innovative approach to muscle recovery and the treatment of sarcopenia
5	DUFRESNE	Regis	Post-Authorisation Safety Study (PASS) of mexiletine treatment in patients with Non-Dystrophic Myotonia (NDM): methodology and safety update
6	LEFEBVRE	Suzie	Functional link between SMN-complex component GEMIN5 and demethylase KDM6B in flunarizine-mediated neuroprotection of spinal muscular atrophy
7	LUCAS	Antoine	Efficacy and safety of nipocalimab in patients with generalized myasthenia gravis: topline results from the double-blind, placebo-controlled, randomized phase 3 vivacity-mg study
8	LUCAS	Antoine	Nipocalimab dose selection for a phase 3 study in adult patients with generalized myasthenia gravis
9	MARCHADIER	Brice	Etude comparative à long terme : efficacité et tolérance chez les enfants atteints d'amyotrophie spinale (SMA) de type 1 traités par risdiplam versus ceux traités par nusinersen
10	MARCHADIER	Brice	Bioéquivalence et évaluation de l'effet des aliments d'une nouvelle formulation de comprimés de risdiplam chez des volontaires sains
11	MONCHEAUX	Alice	Modulating BIN1 as a therapeutic strategy to treat caveolinopathies in mice
12	PARISEL	Eléonore	Profiling of vaccine-induced inflammatory response in human skeletal muscle and association with reactogenicity profile
13	NEFF	Laurence	Development of PROTACs for treating neuromuscular disorders: a prospective collaborative project
14	REISS	Muriel	Exploring higher doses of nusinersen in spinal muscular atrophy: final results from Part B of the 3-part DEVOTE study
15	REISS	Muriel	The open-label phase 4 RESPOND study evaluating nusinersen in children with spinal muscular atrophy (SMA) previously treated with onasemnogene abeparvovec: Interim clinical, neurofilament, and safety results.
16	SLIKA	Rasha	Impact of HDAC6 Inhibition on Muscle Atrophy in Spinal Muscular Atrophy
17	AFANASEVA	Liudmila	Understanding nucleus-mitochondria cross-talk in a premature aging mouse model



21^{ème} Édition

Journées de la Société Française de Myologie

20 - 22 Novembre 2024 | Polydome Clermont-Ferrand



Liste des Posters

#	NOM	PRÉNOM	TITRE DE L'ABSTRACT
18	BELOTTI	Edwige	H2A.Z maintains genome stability by preventing DNA mutation accumulation
19	CHARPENTIER	Clara	Characterization of alpha2delta4 in exertional heat stroke
20	CHENANE	Linda	Deciphering the link between interferon stimulated genes and regeneration using spatial transcriptomics in Dermatomyositis biopsies
21	KRETZ-REMY	Carole	Involvement of SH3KBP1 (Cin85) in the modulation of ER architecture and autophagic process during myotube formation
22	MARTIN	Ludovic	Unraveling Interferon-Related Autophagic Signatures in Immune Myopathies
23	MERLET	Angèle	Proteomic features of patients suspected of X-linked myopathy with excessive autophagy.
24	PINTART	Alexandre	Skeletal muscle regeneration during aging: a benefic aspect of LSD1 depletion?
25	SHIVARAMAN	Shivashakthi	Unveiling early aging in collagen VI Bethlem Myopathy using a zebrafish model
26	CHAUVAUD	Zélia	Impacts of chronic activation of TGF- β signaling on muscle metabolism
27	DAUVOIS	Camille	SR Ca ²⁺ release in mouse muscle fibers expressing human RyR1 variants
28	DEMESMAY	Léa	Are voltage-gated Na ⁺ channels useless for zebrafish twitch muscle fiber to twitch?
29	GELIN	Maxime	Exploring the role of GDF5 in neuromuscular system during growth and physical activity
30	GUILLEMAUD	Jules	Neuromuscular electrical stimulation training promotes myonuclear accretion and increases the number of macrophages and fibroadipogenic progenitors without muscle damage
31	IDRIS	Tahir	STIM1 and STIM1L in human skeletal muscle architecture
32	HOGREL	Jean-Yves	Suivi de la motricité des patients à domicile: le projet DT4RD
33	KACHAL	Abdessamad	Survival and predictors of death in the DM1 population, a registry-based study
34	LECONTE	Marine	DNA damage in LMNA-related congenital muscular dystrophy
35	LEFEBVRE	Suzie	Contributions of skeletal muscles to the beneficial effects of flunarizine in spinal muscular atrophy
36	MAZELIN	Laetitia	Chronic activation of TGF β RI signaling in mouse myofibers impairs muscle Excitation-Contraction Coupling involving loss of RyR1/calstabin-1 interaction
37	MILLIET	Kevin	Prix Master : Défauts de mécanotransduction YAP/TAZ dans la myopathie centronucléaire



21^{ème} Édition

Journées de la Société Française de Myologie
20 - 22 Novembre 2024 | Polydome Clermont-Ferrand



Liste des Posters

#	NOM	PRÉNOM	TITRE DE L'ABSTRACT
38	NOLMANS	Axelle	A role for Maged2 in myogenic differentiation and muscle regeneration
39	PETIOT	Anne	RyR1 function in the control of myotubes differentiation
40	SAPALY	Delphine	Dysregulation of muscle cholesterol homeostasis in amyotrophic lateral sclerosis
41	SCHREIBER	Jonathan	Excitation-contraction coupling in muscle fibers from the mTORmKOKI mouse model
42	MAGOT	Armelle	Expérience patient chez des adultes atteints d'amyotrophie spinale : intégrer une démarche d'analyse dans trois centres de référence neuromusculaire
43	MARCHADIER	Brice	Évaluation rétrospective de l'alimentation et de la nutrition après 2 ans de traitement par risdiplam chez des enfants atteints de SMA de type 1 à l'aide d'une nouvelle échelle
44	MARCHADIER	Brice	FIREFISH Parties 1 et 2 : efficacité et tolérance à 5 ans de risdiplam dans l'amyotrophie spinale (SMA) de type 1
45	RIBAULT	Shams	Quality of life and participation of adults with spinal muscular atrophy : QOLSMA
46	TYRODE	Olivia	L'efgartigimod améliore systématiquement la qualité de vie chez les patients anti-RACH+ atteints de MGg dans les essais IV et SC
47	DEMERET	Sophie	Corticosteroid dose tapering during treatment with zilucoplan in patients with generalised myasthenia gravis: 120-week follow-up of RAISE-XT
48	LAMAIBDEL	Abdelhaq	Description phénotypique atypique chez un nouveau né présentant un possible Syndrome myasthénique congénital lié à LRP4
49	NADAJ-PAKLEZA	Aleksandra	Early responders with zilucoplan: An interim analysis of RAISE-XT in patients with generalised myasthenia gravis
50	SACCONI	Sabrina	Response to rozanolixizumab in patients with generalised myasthenia gravis (gMG) from the Phase 3 MycarinG study
51	SACCONI	Sabrina	Rozanolixizumab treatment patterns in patients with generalised myasthenia gravis: Post hoc analysis
52	TYRODE	Olivia	Atteinte d'une expression minimale des symptômes (MSE) chez les patients myasthéniques traités par l'efgartigimod dans les études ADAPT+ et ADAPT-SC+
53	TYRODE	Olivia	Réduction de l'utilisation de corticoïdes oraux en vie réelle après l'introduction d'efgartigimod
54	BESSE-PINOT	Elsa	Late-onset and atypical Pompe disease revealing Mucopolysaccharidosis type IIIA.
55	LABELLA	Beatrice	Glycogenosis type XI, a rare association between muscle and skin manifestations - the contribution of proteomics for the understanding of the underlying myopathology

21^{ème} Édition

Journées de la Société Française de Myologie

20 - 22 Novembre 2024 | Polydome Clermont-Ferrand



Liste des Posters

#	NOM	PRÉNOM	TITRE DE L'ABSTRACT
56	MARTINEZ	Caroline	Effect size analysis: cipaglicosidase alfa+miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease
57	AUTHIER	F. Jérôme	Muscular involvement in systemic sclerosis: Increased risk of pulmonary event in fibrosing phenotype
58	LABELLA	Beatrice	Toxic autophagic vacuolar myopathies and the role of human leukocyte antigen class I molecules and membrane attack complex in its pathogenesis
59	LESSARD	Lola	A valuable asset for clinical and translational research: MYOLYON, a registry of 1,092 patients with inflammatory myopathies
60	SOUVANNANORATH	Sarah	Amylose musculaire : Etude rétrospective clinique et histologique sur une série de 19 patients
61	METAY	Corinne	Limites du NGS sur ADN génomique : Intérêt des études fonctionnelles dans le diagnostic d'une dystrophie musculaire congénitale d'Ullrich
62	BANOS	Ghislain	Engineered 3D muscle constructs recapitulating the muscle defects of Duchenne Muscular Dystrophy
63	BLEUZEN	Anaïs	Engineered 3D human muscles based on novel biomimetic scaffolds associated with human Muscle Stem Cells or human iPSC-derived myoblasts
64	FRAYSSE	Bodvael	Development of The MyoStretch Platform for Muscle Organoid Maturation
65	MOULY	Vincent	Human myoblasts and FAPs cell lines: easy-to-use models to study neuromuscular diseases
66	NEFF	Laurence A.	Tet-On Transgene Optimization (TOTO): a prospective collaborative project
67	KOURTZAS	Dimitrios	Refined pro-fibrotic in vitro models for detailed extracellular matrix analysis in collagen VI-related dystrophies
68	LAFABRIE	Emma	In vitro validation of a novel STIM1 mutation leading to TAM/STRMK syndrome
69	MORETTA	Antonio	Proteomics analysis of extracellular matrix proteins in dystrophic and regenerating skeletal muscle and their impact on cell behavior
70	PION	Emmanuelle	2024 update of the National French consensus on gene lists for the diagnosis of muscle diseases using high-throughput sequencing
71	BASSEZ	Guillaume	RevEal the burdeN on daily life for myotonic dyStrophy patients due to myotonia (ENSA) survey: key findings
72	BOESPFLUG TANGUY	Odile	Givinostat effects on DMD pathogenesis
73	DAVION	Jean-Baptiste	Theory of mind in myotonic dystrophy type 1 is associated with cortical gyrification and white matter hyperintensities

21^{ème} Édition

Journées de la Société Française de Myologie

20 - 22 Novembre 2024 | Polydome Clermont-Ferrand



Liste des Posters

#	NOM	PRÉNOM	TITRE DE L'ABSTRACT
74	DE LUCIA	Silvana	The Epidys Givinostat Study in DMD: supportive results
75	DELAGE	Erwan	Initial Data from the DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping
76	DELAGE	Erwan	Initial Data from the ACHIEVE Trial of DYNE-101 in Adults with Myotonic Dystrophy Type 1 (DM1)
77	DELAGE	Erwan	The FORCETM platform achieves robust and durable DUX4 suppression and improves muscle function in facioscapulohumeral muscular dystrophy mouse model
78	GOUSSE	Gaëlle	Conception d'un programme d'éducation thérapeutique pédiatrique sur l'activité physique adaptée : « Bouge ton body et muscle ta santé »
79	ANNULÉ		
80	MICHAUD	Maud	Nouveau variant CAPN3 responsable d'une dystrophie musculaire des ceintures précocement rétractile
81	PÉRÉON	Yann	Givinostat in Duchenne muscular dystrophy: effect on disease milestones
82	RIBAULT	Shams	Sensitivity to change of the Motor Function Measure (MFM) in myotonic dystrophy type 1
83	PUECH	Paul	Effect of ataluren on upper limb function in nmDMD patients from the STRIDE Registry
84	PUECH	Paul	Age at loss of ambulation in patients with nmDMD from the STRIDE Registry: sensitivity analyses
85	SANSON	Benoît	Atypical features and predictors in FSHD1: Analysis of the French FSHD registry data
86	BEN DAOUD	Imane	Unlocking Undiagnosed Muscular Dystrophies using Patient's Induced Pluripotent Stem Cells
87	CAILLOL	Damien	Glutamylation of the microtubule network during muscle fiber formation and maturation
88	CERVERA	Chloé	Development of an in vivo model for studying muscle regeneration in the context of whole-body irradiation
89	CHEBOUTI	Sarah	PAX3 Orchestrates developmental trajectories during early mouse organogenesis
90	CICCIARELLO	Delia	The AMPKa2/PHF2 axis is critical for turning over lipid droplets during muscle stem cell fate transition
91	DUPONT	Olivier	Distinct roles of STIM2.1 and STIM2.2 in human myotube formation and function
92	FOURGEAUD	Mélanie	Orai3 and AHNK2 regulate the activation of human skeletal muscle stem cells in vitro
93	GIROUSSE	Amandine	Intramuscular adipocytes: unsuspected crucial partners for muscle regeneration?
94	JOMARD	Charline	Effect of analgesic treatments on voluntary activity and muscle regeneration after cardiotoxin injection in mice

21^{ème} Édition

Journées de la Société Française de Myologie

20 - 22 Novembre 2024 | Polydome Clermont-Ferrand



Liste des Posters

#	NOM	PRÉNOM	TITRE DE L'ABSTRACT
95	KÖNIG	Stéphane	Characterization of skeletal muscles from STIM1L KO mice
96	KURDIAN	Rémi	Genetic clonal analysis of the commitment of PAX3-positive progenitors during embryonic development
97	LEMERLE	Eline	Caveolae and Bin1 form ring-shaped platforms for T-tubule initiation
98	MICHEL	Diego	Human muscle reserve cells are heterogenous for the expression of the chemokine receptor CXCR4
99	MIGNOT	Julien	Development of therapeutic strategies for Volumetric Muscle Loss repair based on innovative hydrogels associated with human MuSC or hiPSC-derived myoblasts
100	MORIN	Loeva	Modeling the muscular phenotype of facioscapulohumeral dystrophy (FSHD)
101	ROTARD	Ludivine	Development of a cilia-targeted protein kinase A biosensor for muscle cells
102	SAUGUES	Audrey	Metabolic regulation of adult muscle stem cells during asynchronous muscle regeneration
103	SCIONTI	Isabella	PKA-induced regulation of the lysine demethylase complex PHF2-LSD1 promotes muscle stem cell commitment
104	SITOLLE	Julie	Using single-nuclei RNA sequencing (snRNA-seq) of regenerating muscle to undercover new potential fusogens in mice
105	TOLLANCE	Axel	Platelet-rich plasma promotes the expansion of human myoblasts and favors the in vitro generation of human muscle reserve cells in a deeper state of quiescence
106	ZMOJDZIAN	Monika	Modelling undiagnosed RYR1 variants in Drosophila
107	ZOGLIO	Virginia	PAX3 drives functional muscle stem cell heterogeneity during muscle regeneration
108	DOBRESCU	Amelia	SUCLG1 uncertain significance variants and a MDDS 9 phenotype - which NGS result do we trust?
109	VELIA	Cécile	Large Language Model as Diagnostic Tool in Distal Myopathies. Comparing AI Prediction and Molecular Diagnosis
110	BERGAS BUADES	Maria	Exploring anti-fibrotic therapies for Oculopharyngeal Muscular Dystrophy: from drug screening to in vivo validation
111	BOUTONNET	Lauréline	An unexplored autophagic function of NUA1 in striated skeletal muscle